PR
    Pharmacy Remedy

    Kadcyla (trastuzumab emtansine) supply for hospitals & distributors

    HER2-directed antibody–drug conjugate · Roche

    Kadcyla (trastuzumab emtansine, T-DM1) is Roche's antibody–drug conjugate that combines trastuzumab with the microtubule inhibitor DM1. It is supplied as a lyophilised powder in two vial sizes for reconstitution and IV infusion.

    اقرأ هذه الصفحة بالعربية

    Prescription-only medicine. No prices are published. Supply is to hospitals, distributors, pharmacies and physicians against a valid prescription or purchase order. This page is product information, not medical advice.

    Product facts

    Active substancetrastuzumab emtansine
    ClassHER2-directed antibody–drug conjugate
    Manufacturer (marketing authorisation holder)Roche
    RouteIntravenous infusion

    Strengths and presentation

    • 100 mg powder for concentrate for solution for infusion, single-use vial
    • 160 mg powder for concentrate for solution for infusion, single-use vial

    Approved indications (EMA / FDA label summary)

    • HER2-positive early breast cancer with residual invasive disease after neoadjuvant taxane and HER2-targeted therapy (adjuvant)
    • HER2-positive unresectable locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane

    Short label summary only. Approved indications differ by country and line of therapy; the national label in the destination country governs.

    Storage and cold chain

    • Store refrigerated at 2–8 °C in the original carton to protect from light
    • Do not freeze; do not shake
    • Shipped in validated cold-chain packaging with temperature data logging

    How we supply

    • Original manufacturer packs only — sourced from licensed wholesalers in Türkiye and Europe, never repackaged or relabelled.
    • Batch number and expiry confirmed in writing before dispatch; every pack is traceable to its batch.
    • Documents with every consignment: commercial invoice, batch / CoA information from the source, and packing list.
    • Validated 2–8 °C cold-chain shipping with a temperature data logger from origin to handover.
    • Named-patient and special-import support: we prepare the paperwork your hospital or importer needs for the local regulator.

    Procurement notes

    Kadcyla is dosed at 3.6 mg/kg every 3 weeks, so pharmacies usually combine 100 mg and 160 mg vials to match patient weight. Share the weight band and number of cycles and we will quote the vial combination. Kadcyla must not be substituted with trastuzumab or trastuzumab deruxtecan.

    Who we supply

    • Hospital pharmacy and procurement departments
    • Licensed pharmaceutical distributors and importers
    • Oncology and haematology centres
    • Treating physicians arranging named-patient supply

    Markets served

    United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Oman, Bahrain and Iraq. Import into each country follows that country's regulator (for example MOHAP / DoH / DHA, SFDA, MoPH, Kuwait MOH, Oman MOH, NHRA) — we work with the receiving institution's import route.

    Frequently asked questions

    Which Kadcyla vial sizes can you supply?

    Both the 100 mg and 160 mg single-use vials in the original Roche carton, with batch and expiry confirmed in writing before dispatch.

    Is Kadcyla the same as Herceptin or Enhertu?

    No. Kadcyla (trastuzumab emtansine), Herceptin (trastuzumab) and Enhertu (trastuzumab deruxtecan) are different medicines with different labels. Orders must name the exact product.

    Is the Kadcyla you supply an original manufacturer pack?

    Yes. We supply Kadcyla only in the original Roche pack, sourced from licensed wholesalers in Türkiye and Europe, never repackaged or relabelled.

    Which documents come with a consignment?

    Commercial invoice, batch / CoA information from the source and a packing list, with batch number and expiry for every pack. Additional documents requested by your importer can be prepared.

    Do you supply the UAE, Saudi Arabia, Qatar, Kuwait, Oman, Bahrain and Iraq?

    Yes — to hospitals, distributors and licensed centres in these countries, through the import or named-patient route accepted by the destination country's regulator.

    How do I get a quote for Kadcyla?

    Send a supply inquiry on WhatsApp with strength, quantity, country and institution. We reply with a written quote, availability and expiry; we do not publish prices on the site.

    Send a supply inquiry

    Tell us the product, strength, quantity, destination country and the receiving institution. We reply with availability, batch/expiry and the documentation set — and a written quote. We do not sell to the public.

    Send a supply inquiry

    Other medicines we supply to the Gulf

    Sources

    Reviewed by Pharmacy Remedy Pharmacovigilance & Compliance Desk · Last updated: 2026-11-04